- Home
- DEA vs MDXG Comparison
DEA vs MDXG Comparison
Compare DEA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- MDXG
- Stock Information
- Founded
- DEA 2011
- MDXG 2006
- Country
- DEA United States
- MDXG United States
- Employees
- DEA N/A
- MDXG N/A
- Industry
- DEA Real Estate Investment Trusts
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- MDXG Health Care
- Exchange
- DEA Nasdaq
- MDXG Nasdaq
- Market Cap
- DEA 1.2B
- MDXG 1.1B
- IPO Year
- DEA 2015
- MDXG N/A
- Fundamental
- Price
- DEA $11.64
- MDXG $9.14
- Analyst Decision
- DEA Buy
- MDXG Strong Buy
- Analyst Count
- DEA 2
- MDXG 5
- Target Price
- DEA $12.50
- MDXG $12.00
- AVG Volume (30 Days)
- DEA 1.2M
- MDXG 637.3K
- Earning Date
- DEA 02-25-2025
- MDXG 02-26-2025
- Dividend Yield
- DEA 9.10%
- MDXG N/A
- EPS Growth
- DEA N/A
- MDXG N/A
- EPS
- DEA 0.17
- MDXG 0.52
- Revenue
- DEA $302,121,000.00
- MDXG $342,804,000.00
- Revenue This Year
- DEA N/A
- MDXG $9.56
- Revenue Next Year
- DEA $9.77
- MDXG $9.19
- P/E Ratio
- DEA $68.24
- MDXG $17.54
- Revenue Growth
- DEA 2.98
- MDXG 10.93
- 52 Week Low
- DEA $10.76
- MDXG $5.47
- 52 Week High
- DEA $14.53
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- DEA 53.07
- MDXG 53.81
- Support Level
- DEA $10.99
- MDXG $8.50
- Resistance Level
- DEA $11.68
- MDXG $9.71
- Average True Range (ATR)
- DEA 0.23
- MDXG 0.29
- MACD
- DEA 0.08
- MDXG -0.02
- Stochastic Oscillator
- DEA 94.96
- MDXG 52.89
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.